Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 30, 2026
Institutional reporting unit files a dated ownership amendment
$HIMSDigital healthcareConsumer healthLegal and execution risk
HIMS Stock Hub: Hims & Hers News, Peptides and Cash Conversion
Hims & Hers is expanding consumer healthcare services while managing a lower-margin sales mix, acquisition payments and unresolved legal matters. Second-quarter revenue was $753.2 million, with a $86.3 million net loss. On October 29 it previewed Peptides+, a planned service rather than a completed launch. The October 30 regular-session close was $27.68.
Full research report · PDF
Hims & Hers Health ($HIMS), research as of October 28, 2026
16 pages covering the operating business, clinical evidence, financial resources, capital structure and dated scenarios. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next scheduled financial catalyst
November 9, 2026
Third-quarter results after the close, followed by a 5:00 p.m. ET call. Primary source
Peptides+ launch timing has not been announced in the October 29 preview; planned access and a waitlist are not current revenue.
HIMS stock at a glance
Close · October 30, 2026
$27.68
Regular session; -6.71% versus $29.6700 on October 29.
Operating result quarter ended June 30, 2026
−$97.2M
The filed operating loss accompanies Q2 revenue of $753.2 million. Revenue growth does not by itself show operating profitability.
Shares outstanding August 7, 2026 cover date
233.313M
233,313,413 Class A and Class V shares reported on the filing cover. The classes have identical economic rights; Class V carries 175 votes per share. This is a dated share count, not a current market valuation.
Cash and short-term securities filed, June 30, 2026
$841.0M
$609.8 million of cash plus $231.2 million of short-term available-for-sale securities, against $1.4025 billion of convertible notes at face value and a working-capital deficit of $98.6 million
Revenue filed, quarter to June 30, 2026
$753.2M
Up 38 per cent on $544.8 million, including one month of Eucalyptus. Gross margin 64 per cent (76 per cent a year earlier); operating loss $(97.2) million; net loss $(86.3) million
2026 guidance company, Aug. 10, 2026
$3.1–$3.3B
Revenue range raised $300 million at both ends since May; Adjusted EBITDA $275–$325 million, a midpoint of $300 million against $337.5 million in February. Company guidance, not our estimate
Subscribers filed, June 30, 2026
2.891M
Up 19% year on year, including acquired subscribers. Monthly revenue per average subscriber was $92, or $90 excluding Eucalyptus; definitions can differ across companies.
Operating cash flow six months ended June 30, 2026
+$53.4M
Q2 alone used $35.9 million. First-half company-defined free cash flow was negative $15.2 million after capital and software investment.
Where Hims & Hers Health stands now
Hims & Hers combines recurring consumer healthcare relationships with medicine fulfilment, clinical support and an expanding international network. The opportunity is to build durable customer relationships across more services and geographies. The immediate question is how much profit and cash the larger revenue base can produce after product costs, marketing and investment. Eucalyptus contributed one month to Q2 and changes the comparison base for future reports. Subscriber growth is therefore not a clean measure of organic acquisition, while revenue per average subscriber includes one-time purchasers. Both metrics remain useful when read with their definitions.
The main constraint. Lower margins, legal costs and acquisition obligations can absorb the benefits of higher sales. Weaker collections or operating results could increase reliance on financing or equity settlement. The outcome depends on cash generation and contractual choices, not revenue growth alone.
The constructive case
A broader product range and international acquisitions can support growth if incremental gross profit translates into cash after marketing, fulfilment and integration costs. Delivery of Q3 guidance with stabilising margins and timely rebate collection would support that reading.
The cautious case
Lower margins, legal costs and acquisition obligations can absorb the benefits of higher sales. Weaker collections or operating results could increase reliance on financing or equity settlement. The outcome depends on cash generation and contractual choices, not revenue growth alone.
Latest Hims & Hers Health news
October 30, 2026
Institutional reporting unit files a dated ownership amendment
The institutional reporting entity reported beneficial ownership of 11,190,115 shares, or 4.97%, as of September 30. The filing describes a disaggregated reporting unit and ordinary-course holdings; it does not establish an activist position.
October 29, 2026
Peptides+ specialty previewed; launch remains prospective
The company previewed its planned Peptides+ specialty and a customer waitlist. It said availability of further therapies depends on what is allowable, acknowledged limited clinical evidence and retained uncertainty around launch timing and policy.
October 29, 2026
Legal officer reports a sale under an existing trading plan
The Form 4 reports 3,462 Class A shares sold on October 28 at $27.60 under a Rule 10b5-1 plan adopted May 21. The filing is a dated insider transaction, not evidence about a new company financing.
October 28, 2026
HHS issues a draft enforcement discretion policy on 503A compounding with six peptides — October 28, 2026
On October 28, 2026 the Office of the Secretary of HHS announced the availability of a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (docket HHS-OASH-2026-0496), scheduled for publication in the Federal Register on October 30. HHS says it does not intend to take enforcement action against a State-licensed pharmacy, a Federal facility or a licensed physician compounding a drug product with a peptide bulk drug substance listed in the policy’s Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The draft policy is interim: it applies while the list of bulk drug substances that can be used in compounding under section 503A is developed through rulemaking, and future FDA rulemakings may propose adding some or all of these peptides to that list. HHS notes that compounded drugs are not FDA-approved. It may revisit the policy in whole or in part, for example if a safety signal or a product quality issue arises, and the policy does not establish rights for any person and is not binding on HHS or the public. Written comments can be submitted through regulations.gov until two weeks after the Federal Register publication date. The notice does not mention Hims & Hers and is reported here as regulatory context. Federal Register notice · Policy document
October 21, 2026
Injectable and oral testosterone therapy added — October 21, 2026
Hims & Hers launched injectable and oral testosterone replacement therapy (TRT) options for eligible men, which the company called its largest men’s health expansion since it first introduced the category last September. The options are a compounded twice-weekly subcutaneous injection, a generic testosterone cypionate taken once a week by intramuscular injection, and Kyzatrex, an FDA-approved oral therapy from Marius Pharmaceuticals; compounded products are not FDA-approved. They add to the existing Testosterone Rx+ treatment based on enclomiphene. Treatment is prescribed by licensed providers after at-home blood testing; the company said that, as of the second quarter, testosterone was its fastest-scaling specialty after weight loss. No financial targets were given. Press release
October 15, 2026
Federal peptide compounding proposal under White House review — October 15, 2026
The HHS/FDA proposal titled “Interim Access Policy for Compounding Using Certain Peptides” was received by the White House Office of Management and Budget on October 14, 2026. The regulatory entry lists it as pending review. According to a report citing people familiar with the plan, it would temporarily allow pharmacies to compound certain unapproved peptides, including BPC-157, under enforcement discretion. This is a reported plan, not an approved policy. Regulatory review entry · Report on the proposed plan
HIMS stock catalysts: results, integration and planned services
- November 9, 2026 — Q3 results after the market close; call at 5:00 p.m. ET. Company-announced date
- Launch date not stated — Peptides+ service preview and waitlist; availability and policy remain conditional. Company plan
HIMS earnings: growth, margins and cash conversion
Q2 revenue was $753.214 million, with a $97.192 million operating loss and $86.290 million net loss. At June 30, cash and short-term investments totalled $841.048 million; first-half operating cash flow was positive $53.417 million, while Q2 alone used $35.939 million. Working capital was negative $98.619 million, alongside convertible debt and acquisition payments.
Eucalyptus and convertible financing obligations
Eucalyptus closed on June 1, 2026. The announced transaction ceiling was up to $1.15 billion, subject to adjustments. The June accounts recorded a $968.5 million purchase price for accounting purposes: $225.0 million paid upfront, $683.9 million of deferred payments and $59.6 million of contingent consideration measured at acquisition-date fair value. These figures describe different measurement bases from the maximum announced transaction value.
The company had two zero-coupon convertible issues at June 30: $1.0 billion principal due May 15, 2030, and $402.5 million principal due June 1, 2032. Their combined principal is $1,402.5 million; the balance-sheet carrying amount was $1,365.299 million after unamortised discounts and issuance costs. Neither principal nor carrying value equals cash currently payable in the next quarter.
Merlintrader Health Score · $HIMS
2.70out of 5
Assessed October 4, 2026. Weighted calculation: 3.0×30% + 2.5×30% + 2.5×20% + 3.0×10% + 2.5×10% = 2.70. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Acquisition-driven subscriber growth does not establish organic growth.
- Legal exposure, compounding policy and clinical evidence can constrain new services.
- Convertible notes and acquisition payments create financing and potential dilution risks.
HIMS Stock FAQ: Hims & Hers Health Questions Answered
When are the next results?
Hims & Hers will report third-quarter 2026 results after the market closes on Monday, November 9, 2026, with a 5:00 p.m. ET call (October 12 release). The quarter ended September 30; August guidance was $880–$900 million revenue and $75–$95 million adjusted EBITDA.
Does subscriber growth measure organic growth?
No. The June count of 2.891 million includes Eucalyptus. Acquisitions, cancellations and new customers all affect the total. The monthly revenue metric also includes revenue from one-time buyers who are not subscribers, so it is not a typical recurring customer invoice.
How much liquidity was reported?
June cash and equivalents plus short-term investments totalled $841.048 million. Revolver availability and an uncommitted receivables programme are separate financing resources, not cash already held. Working capital was negative $98.619 million.
Is the FTC provision the final cost?
No. The approximately $60 million accrual is an accounting estimate for a contested matter. The company said the amount could change materially and could not estimate a reasonably possible loss above it. Potential operating remedies also matter.
Will Eucalyptus necessarily be paid for with new shares?
No. The contracts permit share settlement for a significant majority of specified deferred and earn-out payments within their terms. No Class A shares were issued at closing. Future elections determine the mix of cash and equity.
Primary sources
- October 30, 2026 — Institutional reporting unit files a dated ownership amendment
- October 29, 2026 — Peptides+ specialty previewed; launch remains prospective
- October 29, 2026 — Legal officer reports a sale under an existing trading plan
- October 28, 2026 — HHS issues a draft enforcement discretion policy on 503A compounding with six peptides — October 28, 2026
- October 21, 2026 — Injectable and oral testosterone therapy added — October 21, 2026
- October 15, 2026 — Federal peptide compounding proposal under White House review — October 15, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $HIMS or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Companies in consumer healthcare and telehealth are exposed to regulatory, legal and reputational risk. Regulatory positions can change, legal proceedings can end in outcomes that differ from any accrual, a company with convertible notes and deferred acquisition payments can face dilution or a need to raise capital, and the share price can move sharply on a single report. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
